Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- JPMA Update (6)
October 11, 2004
- ＜Special Contribution＞
October 4, 2004
- JPMA Update (5)
October 4, 2004
- JPMA Update(4)
September 27, 2004
- JPMA Update (3)
September 20, 2004
- JPMA Update (2)
September 13, 2004
- ＜New Series＞
September 6, 2004
-
June 7, 2004
-
May 24, 2004
- BULLETIN
May 24, 2004
- Brand Equity in the Pharmaceutical Industry
March 8, 2004
- ＜Special Contribution＞ Breakthrough Candidates from Japanese Pharmaceutical Industry in 2004 (2)
March 8, 2004
-
March 1, 2004
- Pursuing the Value of the Japanese Pharm Industry (2)
February 9, 2004
- ＜New Series＞ Pursuing the Value of the Japanese Pharm Industry (1)
January 19, 2004
- ＜Special Contribution＞ Happy New Year to Japanese Pharmaceutical Stocks!
January 12, 2004
- ＜Special Contribution＞ Global Products Enhance Dominance in Japan with Local Products Confined to Niche Markets
January 12, 2004
-
November 10, 2003
- ＜Special Contribution＞
November 3, 2003
- ＜Special Contribution＞
September 1, 2003
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…